Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Circio Holding ASALTS:0RIS +6.34%23 EV-to-EBITDA is -55.16 as of Aug. 23, 2026. GuruFocus rates LTS:0RIS with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 406 Biotechnology companies, Circio Holding ASA ranks worse than 246305.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Circio Holding ASA's enterprise value is kr2,521.69 Mil.
Circio Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-45.71 Mil. Therefore, Circio Holding ASA's EV-to-EBITDA for today is -55.16.
The historical rank and industry rank for Circio Holding ASA's EV-to-EBITDA or its related term are showing as below:
LTS:0RIS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -55.16 Med: -1.4 Max: -0.21
Current: -55.16
During the past 13 years, the highest EV-to-EBITDA of Circio Holding ASA was -0.21. The lowest was -55.16. And the median was -1.40.
LTS:0RIS's EV-to-EBITDA is ranked worse than 100% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs LTS:0RIS: -55.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Circio Holding ASA's PE Ratio (TTM) for today is calculated as:
Circio Holding ASA's share price for today is kr9.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Circio Holding ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.426.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Circio Holding ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RIS vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Circio Holding ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Circio Holding ASA EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Circio Holding ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Circio Holding ASA's EV-to-EBITDA falls into.
Circio Holding ASA's current Enterprise Value is kr2,521.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Circio Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-45.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Circio Holding ASA (LTS:0RIS) has a EV-to-EBITDA of -55.16 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Circio Holding ASA. According to the industry distribution chart, Circio Holding ASA ranks #999999 out of 406 companies in the Biotechnology industry.
Is Circio Holding ASA's EV-to-EBITDA too high?
Circio Holding ASA's current EV-to-EBITDA is -55.16. Based on the distribution chart, Circio Holding ASA ranks #999999 out of 406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Circio Holding ASA has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Circio Holding ASA's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Circio Holding ASA ranks #999999 out of 406 companies for EV-to-EBITDA. This places Circio Holding ASA in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Circio Holding ASA. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Circio Holding ASA's current EV-to-EBITDA is -55.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Circio Holding ASA stock overvalued right now?
Circio Holding ASA (LTS:0RIS) has a current EV-to-EBITDA of -55.16. The current EV-to-EBITDA is -55.16. Circio Holding ASA's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Circio Holding ASA (LTS:0RIS), the current EV-to-EBITDA is -55.16 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
23GF Score
Get the complete analysis for LTS:0RIS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RIS has been successfully added to your 
